Top Markets
#1 Black Phoenix Black Phoenix +734.10%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.73%
#3 THORChain THORChain +22.75%
#4 TENDIES TENDIES +17.07%
#5 THORChain Yield THORChain Yield +17.03%
#6 MiL.k Alliance MiL.k Alliance +15.92%
#7 Biconomy Biconomy +15.76%
#8 Gigachad Gigachad +14.96%
#9 Tutorial Tutorial +14.38%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +14.32%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Zai Lab Limited Zai Lab Limited

Zai Lab Limited

ZLAB
Kedudukan dalam Saham #5164
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a... Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Harga Saham
$26.03
Disegerakkan terakhir: 2026-08-26
Modal Pasaran
$2.94B
Perubahan (1 hari)
-0.55%
Perubahan (1 tahun)
-20.07%
Negara
CN
Perdagangan Zai Lab Limited (ZLAB)

Kategori

Healthcare
Pendapatan untuk Zai Lab Limited (ZLAB)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Zai Lab Limited, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Zai Lab Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH